PharmAla Biotech’s P-1 Patent Promises New Treatments

PharmAla Biotech Holdings, Inc. (TSE:MDMA) has released an update.

PharmAla Biotech Holdings Inc. has announced that the US Patent and Trademark Office granted a patent for their novel compound, P-1, which shows promise in treating neurological and psychiatric conditions with a low risk of abuse. The drug, now called APA-001, demonstrated beneficial properties in rodent models, including pro-social behavior and potential for inducing neuroplasticity. With its readiness for pre-clinical and clinical development, APA-001 could revolutionize the treatment of psychological trauma, brain injuries, and fear disorders.

For further insights into TSE:MDMA stock, check out TipRanks’ Stock Analysis page.